Thrivent Financial for Lutherans Has $488,000 Holdings in Sanofi (NASDAQ:SNY)

Thrivent Financial for Lutherans decreased its stake in shares of Sanofi (NASDAQ:SNYGet Rating) by 2.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 10,083 shares of the company’s stock after selling 300 shares during the period. Thrivent Financial for Lutherans’ holdings in Sanofi were worth $488,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Millington Financial Advisors LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $778,000. Equity Investment Corp lifted its position in Sanofi by 24.1% during the 4th quarter. Equity Investment Corp now owns 1,927,433 shares of the company’s stock worth $93,346,000 after acquiring an additional 373,685 shares during the last quarter. Boston Partners boosted its holdings in Sanofi by 3.0% during the fourth quarter. Boston Partners now owns 18,246,904 shares of the company’s stock valued at $883,966,000 after acquiring an additional 523,705 shares during the period. Lincoln National Corp grew its position in shares of Sanofi by 6.2% in the fourth quarter. Lincoln National Corp now owns 5,747 shares of the company’s stock valued at $278,000 after purchasing an additional 338 shares during the last quarter. Finally, Conning Inc. acquired a new position in shares of Sanofi during the 4th quarter worth about $220,000. 10.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft cut Sanofi from a “hold” rating to a “sell” rating in a research report on Friday, April 28th. Barclays upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating in a research note on Monday, March 27th. lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 13th. Finally, Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, March 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. According to data from, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.50.

Sanofi Stock Performance

Sanofi stock opened at $52.59 on Friday. The firm has a market capitalization of $132.63 billion, a P/E ratio of 18.85, a P/E/G ratio of 1.78 and a beta of 0.57. The stock has a fifty day moving average price of $54.95 and a two-hundred day moving average price of $51.42. Sanofi has a 52-week low of $36.91 and a 52-week high of $57.82. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.42 and a quick ratio of 1.05.

Sanofi (NASDAQ:SNYGet Rating) last announced its earnings results on Thursday, April 27th. The company reported $1.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.06. The business had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.60 billion. Sanofi had a net margin of 15.41% and a return on equity of 28.45%. As a group, analysts anticipate that Sanofi will post 4.46 EPS for the current fiscal year.

Sanofi Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 23rd. Stockholders of record on Wednesday, May 31st will be issued a $1.377 dividend. This represents a dividend yield of 2.94%. The ex-dividend date is Tuesday, May 30th. Sanofi’s payout ratio is currently 45.16%.

About Sanofi

(Get Rating)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.

Read More

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.